L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study

BMC Cancer

Panagiota-Aikaterini Geomela¹  Christos K Kontos¹  Ioannis Yiotakis²  Emmanuel G Fragoulis¹  Andreas Scorilas¹ 

[1] Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, Athens 15701, Greece

[2] First Ear, Nose & Throat Clinics, Athens General Hospital ‘Hippokration, University of Athens, 114 Vasilissis Sofias Ave, Athens 11527, Greece

关键词: Quantitative real-time PCR;    Tumor biomarkers;    Tongue;    Larynx;    Oral cancer;   

Others  :  1080126
DOI  :  10.1186/1471-2407-12-484

 received in 2012-06-19, accepted in 2012-10-17,  发布年份 2012

【 摘 要 】

Background

Head and neck squamous cell carcinoma (HNSCC) represents one of the most commonly diagnosed malignancies worldwide. The DDC gene encodes L-DOPA decarboxylase, an enzyme catalyzing the decarboxylation of L-DOPA to dopamine. We have recently shown that DDC mRNA is a significant predictor of patients’ prognosis in colorectal adenocarcinoma and prostate cancer. The aim of the current study was to analyze the DDC mRNA expression in HNSCC patients.

Methods

53 malignant tumors were resected from the larynx, pharynx, tongue, buccal mucosa, parotid glands, and nasal cavity, as well as from 34 adjacent non-cancerous tissues of HNSCC patients, and were homogenized. Total RNA was isolated and converted into first-strand cDNA. An ultrasensitive real-time PCR method based on the SYBR Green chemistry was used for DDC mRNA quantification in head and neck tissue specimens. Relative quantification was performed using the comparative Ct (2^-ddCt) method.

Results

DDC mRNA levels were lower in squamous cell carcinomas (SCCs) of the larynx and tongue than in adjacent non-cancerous tissue specimens. Furthermore, low DDC mRNA expression was noticed in laryngeal and tongue tumors of advanced TNM stage or bigger size, compared to early-stage or smaller tumors, respectively. No statistically significant differences were observed between SCCs resected from pharynx, buccal mucosa, or nasal cavity, and their normal counterparts.

Conclusion

This is the first study examining the DDC mRNA expression in HNSCC. According to our results, DDC mRNA expression may constitute a potential prognostic biomarker in tongue and/or larynx SCCs, which principally represent the overwhelming majority of HNSCC cases.

【 授权许可】

   
2012 Geomela et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, Coman WB: Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 2006, 6:1111-1118.
• [2]Perez-Ordonez B, Beauchemin M, Jordan RC: Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006, 59:445-453.
• [3]Argiris A, Karamouzis MV, Raben D, Ferris RL: Head and neck cancer. Lancet 2008, 371:1695-1709.
• [4]Chan AT, Teo PM, Johnson PJ: Nasopharyngeal carcinoma. Ann Oncol 2002, 13:1007-1015.
• [5]Busson P, Keryer C, Ooka T, Corbex M: EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 2004, 12:356-360.
• [6]Patel SG, Shah JP: TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 2005, 55:242-258. quiz 261-242, 264
• [7]Lothaire P, de Azambuja E, Dequanter D, Lalami Y, Sotiriou C, Andry G, Castro G Jr, Awada A: Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 2006, 28:256-269.
• [8]Ichinose H, Kurosawa Y, Titani K, Fujita K, Nagatsu T: Isolation and characterization of a cDNA clone encoding human aromatic L-amino acid decarboxylase. Biochem Biophys Res Commun 1989, 164:1024-1030.
• [9]O’Malley KL, Harmon S, Moffat M, Uhland-Smith A, Wong S: The human aromatic L-amino acid decarboxylase gene can be alternatively spliced to generate unique protein isoforms. J Neurochem 1995, 65:2409-2416.
• [10]Vassilacopoulou D, Sideris DC, Vassiliou AG, Fragoulis EG: Identification and characterization of a novel form of the human L-dopa decarboxylase mRNA. Neurochem Res 2004, 29:1817-1823.
• [11]Ichinose H, Sumi-Ichinose C, Ohye T, Hagino Y, Fujita K, Nagatsu T: Tissue-specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylase. Biochemistry 1992, 31:11546-11550.
• [12]Krieger M, Coge F, Gros F, Thibault J: Different mRNAs code for dopa decarboxylase in tissues of neuronal and nonneuronal origin. Proc Natl Acad Sci USA 1991, 88:2161-2165.
• [13]Christenson JG, Dairman W, Udenfriend S: On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic L-amino acid decarboxylase-serotonin-dopamine-norepinephrine). Proc Natl Acad Sci USA 1972, 69:343-347.
• [14]Chalatsa I, Fragoulis EG, Vassilacopoulou D: Release of membrane-associated L-dopa decarboxylase from human cells. Neurochem Res 2011, 36:1426-1434.
• [15]Florou D, Scorilas A, Vassilacopoulou D, Fragoulis EG: DDC (dopa decarboxylase (aromatic L-amino acid decarboxylase)). Atlas Genet Cytogenet Oncol Haematol 2011, 15:949-957.
• [16]Siaterli MZ, Vassilacopoulou D, Fragoulis EG: Cloning and expression of human placental L-Dopa decarboxylase. Neurochem Res 2003, 28:797-803.
• [17]Kokkinou I, Nikolouzou E, Hatzimanolis A, Fragoulis EG, Vassilacopoulou D: Expression of enzymatically active L-DOPA decarboxylase in human peripheral leukocytes. Blood Cells Mol Dis 2009, 42:92-98.
• [18]Kokkinou I, Fragoulis EG, Vassilacopoulou D: The U937 macrophage cell line expresses enzymatically active L-Dopa decarboxylase. J Neuroimmunol 2009, 216:51-58.
• [19]Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
• [20]Margiotti K, Wafa LA, Cheng H, Novelli G, Nelson CC, Rennie PS: Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells. Mol Cancer 2007, 6:38. BioMed Central Full Text
• [21]Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski I, Rennie PS: Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. Biochem J 2003, 375:373-383.
• [22]Vassiliou AG, Fragoulis EG, Vassilacopoulou D: Detection, purification and identification of an endogenous inhibitor of L-Dopa decarboxylase activity from human placenta. Neurochem Res 2009, 34:1089-1100.
• [23]Vassiliou AG, Vassilacopoulou D, Fragoulis EG: Purification of an endogenous inhibitor of L-Dopa decarboxylase activity from human serum. Neurochem Res 2005, 30:641-649.
• [24]Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila RI, Mulshine JL, Schuller HM, Park JG: Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 1988, 48:4078-4082.
• [25]Gilbert JA, Bates LA, Ames MM: Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors. Biochem Pharmacol 1995, 50:845-850.
• [26]Ippolito JE, Xu J, Jain S, Moulder K, Mennerick S, Crowley JR, Townsend RR, Gordon JI: An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad Sci USA 2005, 102:9901-9906.
• [27]Gilbert JA, Frederick LM, Ames MM: The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res 2000, 6:4365-4372.
• [28]Jensen SM, Gazdar AF, Cuttitta F, Russell EK, Linnoila RI: A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines. Cancer Res 1990, 50:6068-6074.
• [29]Gilbert J, Haber M, Bordow SB, Marshall GM, Norris MD: Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies. Am J Pathol 1999, 155:17-21.
• [30]Bozzi F, Luksch R, Collini P, Gambirasio F, Barzano E, Polastri D, Podda M, Brando B, Fossati-Bellani F: Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma. Diagn Mol Pathol 2004, 13:135-143.
• [31]Avgeris M, Koutalellis G, Fragoulis EG, Scorilas A: Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer. Clin Biochem 2008, 41:1140-1149.
• [32]Koutalellis G, Stravodimos K, Avgeris M, Mavridis K, Scorilas A, Lazaris A, Constantinides C: L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer. BJU Int 2012, 110:E267-E273.
• [33]Sakakura C, Takemura M, Hagiwara A, Shimomura K, Miyagawa K, Nakashima S, Yoshikawa T, Takagi T, Kin S, Nakase Y, et al.: Overexpression of dopa decarboxylase in peritoneal dissemination of gastric cancer and its potential as a novel marker for the detection of peritoneal micrometastases with real-time RT-PCR. Br J Cancer 2004, 90:665-671.
• [34]Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS: Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 2007, 38:161-170.
• [35]Berry MD, Juorio AV, Li XM, Boulton AA: Aromatic L-amino acid decarboxylase: a neglected and misunderstood enzyme. Neurochem Res 1996, 21:1075-1087.
• [36]Medina MA, Quesada AR, Nunez de Castro I, Sanchez-Jimenez F: Histamine, polyamines, and cancer. Biochem Pharmacol 1999, 57:1341-1344.
• [37]Lang PA, Kempe DS, Akel A, Klarl BA, Eisele K, Podolski M, Hermle T, Niemoeller OM, Attanasio P, Huber SM, et al.: Inhibition of erythrocyte “apoptosis” by catecholamines. Naunyn Schmiedebergs Arch Pharmacol 2005, 372:228-235.
• [38]Kontos CK, Papadopoulos IN, Fragoulis EG, Scorilas A: Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br J Cancer 2010, 102:1384-1390.
• [39]Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
• [40]Rodrigo JP, Ferlito A, Suarez C, Shaha AR, Silver CE, Devaney KO, Bradley PJ, Bocker JM, McLaren KM, Grenman R, Rinaldo A: New molecular diagnostic methods in head and neck cancer. Head Neck 2005, 27:995-1003.
• [41]Sotiriou C, Lothaire P, Dequanter D, Cardoso F, Awada A: Molecular profiling of head and neck tumors. Curr Opin Oncol 2004, 16:211-214.
• [42]Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Ardavanis A, Scorilas A: Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. Tumour Biol 2010, 31:391-399.
• [43]Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Scorilas A: BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. Mol Med 2011, 17:163-171.
• [44]Kontos CK, Scorilas A: Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med CCLM / FESCC 2012. doi: 10.1515/cclm-2012-0247
• [45]Geomela PA, Kontos CK, Yiotakis I, Scorilas A: Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma. J Oral Pathol Med 2012. doi: 10.1111/j.1600-0714.2012.01190.x
• [46]Patsis C, Yiotakis I, Scorilas A: Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. Clin Biochem 2012, 45:623-630.
• [47]Piccirillo JF, Lacy PD, Basu A, Spitznagel EL: Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg 2002, 128:1172-1179.
• [48]Nguyen-Tan PF, Le QT, Quivey JM, Singer M, Terris DJ, Goffinet DR, Fu KK: Treatment results and prognostic factors of advanced T3–4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys 2001, 50:1172-1180.
• [49]Chireux M, Raynal JF, Le Van Thai A, Cadas H, Bernard C, Martinou I, Martinou JC, Weber MJ: Multiple promoters of human choline acetyltransferase and aromatic L-amino acid decarboxylase genes. J Physiol Paris 1994, 88:215-227.
• [50]Sumi-Ichinose C, Hasegawa S, Ichinose H, Sawada H, Kobayashi K, Sakai M, Fujii T, Nomura H, Nomura T, Nagatsu I, et al.: Analysis of the alternative promoters that regulate tissue-specific expression of human aromatic L-amino acid decarboxylase. J Neurochem 1995, 64:514-524.
• [51]Patsis C, Glyka V, Yiotakis I, Fragoulis EG, Scorilas A: L-DOPA decarboxylase (DDC) expression status as a novel molecular tumor marker for diagnostic and prognostic purposes in laryngeal cancer. Transl Oncol 2012, 5:288-296.